Subcutaneous Recombinant Human Erythropoietin for the Treatment of Anemia in Myelodysplastic Syndromes

Abstract
Recombinant human erythropoietin (rhEPO) was administered subcutaneously to 13 anemic (Hb

This publication has 0 references indexed in Scilit: